ReviewJournal of kidney cancer and VHL2017
The Risks of Renal Angiomyolipoma: Reviewing the Evidence.
Review in Journal of kidney cancer and VHL, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 52 citations in OpenAlex.
- Renal angiomyolipoma with inferior vena cava tumor thrombus in a pregnant woman.Radiology case reports · 2026Article
- Epithelioid angiomyolipoma: a rare renal tumor with histopathological complexity.Journal of surgical case reports · 2026Article
- Renal Angiomyolipoma in a Young Woman With Tuberous Sclerosis: A Case Report.Clinical case reports · 2026Article
- Rates of volume reduction after selective arterial embolization for renal angiomyolipoma.Urologic oncology · 2025Article
- Resolution of hypokalemia following nephrectomy for a presumed renal cell carcinoma revealing a large angiomyolipoma: A case report.Urology case reports · 2025Article
- Article
- Revisiting angiomyolipomas: The significance of a rich blood supply on imaging for risk-adapted decision making.Investigative and clinical urology · 2025Article
- Comparison of perioperative efficacy and indications between laparoscopic capsule-preserving resection and partial nephrectomy for renal angiomyolipoma: a decade-long retrospective study.World journal of surgical oncology · 2025Article
- Comparison of Superselective Renal Artery Embolization versus Retroperitoneal Laparoscopic Partial Nephrectomy in Ruptured Hemorrhagic Renal Angiomyolipoma: A Single-Center Study.Diseases (Basel, Switzerland) · 2024Article
- Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex.Cureus · 2024Article
- A Rare Case of Renal Angiomyolipoma and Polycystic Kidney Disease in a Patient with Tuberous Sclerosis.Cureus · 2024Article
- Management of renal sinus angiomyolipoma: modified robotic nephron-sparing surgery in a single center.BMC urology · 2024Article
- Review of the spectrum of tuberous sclerosis complex: The Saudi Arabian Experience.Neurosciences (Riyadh, Saudi Arabia) · 2024Article
- [Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Angiomyolipoma during pregnancy: A forgotten risk factor for rupture and massive haemorrhage - A case report.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2024Article
- Is Size All That Matters? New Predictors of Complications and Bleeding in Renal Angiomyolipoma.Research and reports in urology · 2023Article
- Surgical Conundrum: A Case of Giant Renal Angiomyolipoma Abutting Inferior Vena Cava With Haemorrhage.Cureus · 2022Article
- Ruptured angiomyolipoma, a novel entity for emergency physicians in the differential diagnosis of haemorrhagic shock in a female patient of reproductive age.BMJ case reports · 2022Article
- Transarterial Embolization for Sporadic Renal Angiomyolipoma: Patient Selection and Technical Considerations for Optimal Therapeutic Outcomes.Taehan Yongsang Uihakhoe chi · 2022Review
- New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature.Journal of kidney cancer and VHL · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal angiomyolipoma (RAML), though a rare benign tumor, may impose a significant morbidity or even mortality due to its unique characteristics and the complications subsequent to its treatment. The classic tumor variant is composed of smooth muscular, vascular, and fatty components. The most straightforward diagnosis is when the fat component is abundant and gives a characteristic appearance on different imaging studies. In fat-poor lesions, however, the diagnosis is difficult and presumed a renal cell carcinoma. Yet, some variants of RAML, though rare, express an aggressive behavior leading to metastasis and mortality. The challenge lies in the early detection of benign variants and identifying aggressive lesions for proper management. Another challenge is when the vascular tissue component predominates and poses a risk of hemorrhage that may extend to the retroperitoneum in a massive life-threatening condition. The predicament here is to identify the characteristics of tumors at risk of bleeding and provide a prophylactic treatment. According to the clinical presentation, different treatment modalities, prophylactic or therapeutic, are available that span the spectrum of observation, embolization, or surgery. Renal impairment may result from extensive tumor burden or as a complication of the management itself. Improvement of diagnostic techniques, super-selective embolization, nephron-sparing surgery, and late treatment with the mammalian target of rapamycin inhibitors have provided more effective and safe management strategies. In this review, we examine the evidence pertaining to the risks imposed by RAML to the patients and identify merits and hazards associated with different treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.